Yiwei Li

FDA investigator

Appears on 7 documents from 2023 to 2025, most often at sites in China. Most often cites general requirements (21 CFR 211.160).

7
Documents on file
9.0
Observations per 483
2023
First seen
2025
Most recent

What they cite most

From 62 observations

Activity by year

2023: 2, 2024: 2, 2025: 3

Where

China 3 · North Carolina 2 · Indiana 1 · South Korea 1

Is Yiwei Li coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

7 documents, newest first
FirmOpen
483 Aurolife Pharma LLCApr 10, 2025 · Durham, North Carolina
483 Aurige Pharma LLCMar 24, 2025 · Durham, North Carolina
483 Bio-Thera Solutions, LtdJan 17, 2025 · Huangpu Di strict, China
483 STgen Bio Co., Ltd.Jun 25, 2024 · Incheon, South Korea
483 Simtra US LLCFeb 20, 2024 · Bloomington, Indiana
483 Suzhou Suncadia Biopharmaceuticals Co., Ltd.Dec 15, 2023 · Suzhou, China
483 Suzhou Suncadia Biopharmaceuticals Co., LtdDec 14, 2023 · Suzhou, China

About this profile

What does Yiwei Li inspect?

Yiwei Li appears on 7 documents on file covering 5 sites, most often in China.

What do they cite most often?

21 CFR 211.160 (general requirements), followed by 21 CFR 211.192 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Yiwei Li is dated Apr 10, 2025.

FDA Investigator Yiwei Li: 483s & Inspections · FDA Intel